Insulet (GOV) AI Stock Analysis

Insulet

(XETRA:GOV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring consumable revenue modelThe disposable Omnipod model creates recurring revenue as patients replace pods regularly, supporting visibility beyond one-time hardware sales. This repeat usage can strengthen customer retention, improve planning, and provide a durable foundation for continued growth as the installed base expands.

Negative Factors

Type 2 retention execution riskWeak onboarding and first-90-day retention among type 2 customers could reduce the lifetime value of new users and make growth investments less efficient. Although management describes the issue as addressable, corrective actions must improve utilization before this customer segment becomes a durable growth contributor.

Insulet (GOV) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 10.38B
Dividend Yield: ―
Average Volume (3M): 75
Price to Earnings (P/E): 27.9
Beta (1Y): 0.25
Revenue Growth: 20.74%
EPS Growth: 47.73%
Country: Germany
Employees: 5,400
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...

Insulet Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-5.32%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.

Positive Updates

Strong Revenue Growth

Q2 total revenue of $802 million, up 23.5% reported and 22.7% constant currency year-over-year; company delivered another quarter of strong top-line growth.

Negative Updates

Type 2 Retention and Utilization Challenges

Observed lower-than-expected utilization and retention among type 2 customers, especially pronounced in Q2; company attributes the issue to onboarding/first-90-day execution rather than product or pricing.

Company Guidance

Insulet updated 2026 guidance to expect full‑year constant‑currency total company revenue growth of 20–22% and total Omnipod growth of 21–23%, with U.S. Omnipod up 17–19% and international Omnipod up 30–32% (FX expected to add ~100 bps to total/company Omnipod growth and ~300 bps to international); Q3 guidance calls for Omnipod growth of 18–20% and total company growth of 17.5–19.5% (U.S. Omnipod 14–16%, international Omnipod 28–30%) with FX headwinds of ~50 bps to Q3 totals and ~200 bps to international, management still expects ~100 bps of operating‑margin expansion in 2026, roughly $40M of net interest expense, a non‑GAAP tax rate of 20–21%, ~70M shares outstanding, adjusted EPS growth of at least 30% for the year, free cash flow modestly down versus 2025 (YTD FCF $145M) and an exit‑rate into year‑end in the mid‑teens constant‑currency that the company aims to meet or exceed in 2027 (preliminary view assumes competition but not benefits from newly deployed retention actions).

Insulet Risk Analysis

Insulet disclosed 36 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Insulet Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:GOV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	74Outperform	$123.49B	23.60	10.60%	2.96%	9.77%	12.28%
DXCM	73Outperform	$30.69B	31.77	36.50%	―	13.03%	40.88%
ABT	69Neutral	$183.77B	39.33	9.12%	2.37%	10.00%	―
BBNX	60Neutral	$910.65M	-8.96	-27.33%	―	43.69%	-3.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	47Neutral	$1.33B	-20.58	-45.97%	―	3.92%	70.03%

* Healthcare Sector Average

Performance Comparison

DE:GOV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:GOV	Insulet	137.05	-139.75	-50.49%
ABT	Abbott Laboratories	106.20	-14.64	-12.11%
DXCM	Dexcom	82.29	21.86	36.17%
MDT	Medtronic	96.54	9.23	10.58%
TNDM	Tandem Diabetes Care	19.11	4.75	33.08%
BBNX	Beta Bionics, Inc.	16.75	-10.95	-39.53%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Insulet AI Stock Analysis